Author of

• 29740

  +

  PL04 - Food for Thought in the Management of Thoracic Malignancies (ID 91)

  • Event: WCLC 2019
  • Type: Plenary Session
  • Track: Advanced NSCLC
  • Presentations: 1
  • Now Available
  • Moderators:Daniel SW Tan, Ramon Rami-Porta
  • Coordinates: 9/10/2019, 16:15 - 17:00, Barcelona (2005)

  • 29742

    +

    PL04.02 - What Does Survivorship Mean in the World of Immunotherapy (Physical and Financial)? (Now Available) (ID 3596)

    16:15 - 17:00  |  Presenting Author(s): Michelle Turner
    • Abstract
    • Presentation
    • Slides

    Abstract
    

    With improvements in diagnostic, therapeutic, and supportive therapies, the number of cancer survivors

    continues growing with over 20 million cancer survivors worldwide and an estimated 2/3 of adults with

    a cancer diagnosis who are anticipated to be alive in 5 years¹. Due to this increase in survivors, major

    medical societies such as American Society of Clinical Oncology (ASCO), Institute of Medicine (IOM), and

    the Society for Immunotherapy of Cancer’s (SITC) have highlighted the need for strategies to improve

    the ongoing care of survivors and survivorship plans.²

    The 4 basic tenets of a survivorship plan are surveillance, prevention, intervention and coordination.

    Surveillance is aimed at monitoring for recurrence, second cancers, and long term toxicities, prevention

    of these sequelae if possible, intervention if they are found, and lastly coordination between hospital

    and community‐based doctors is essential for this plan to be effective.³ These needs are typically

    communicated to the patient’s general practitioner (GP)/primary care physician (PCP) by a “care plan”

    that outlines the patient’s oncology treatment course, potential long‐term toxicity, the

    frequency of follow up visits, scans and links to community resources.

    New cancer therapies such as immunotherapy has resulted in significantly improved overall survivals in

    many advanced cancers, including those that had formerly been considered refractory.6,7,8 However, the

    short‐, intermediate‐, and long‐term complications of these therapeutic agents are still being identified.

    Immune‐mediated events, for example, can occur immediately after therapy initiation or even up to two

    years post treatment as a consequence of overstimulation of the immune system leading to

    autoimmunity with the potential for permanent or long‐term sequelae.^4,5

    References:

    1. https://cancercontrol.cancer.gov/ocs/statistics/statistics.html

    2. https://www.canceradvocacy.org/

    3. Denlinger, CS et. Al. Survivorship: Introduction and Definition. J Natl Compr Canc Netw. 2014 Jan; 12(1): 34–45.

    4. Sheela S, Kim ES, Mileham KF. Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE‐189J Thorac Dis. 2018 Sep;10(9):5186‐5189.

    5. Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2017; 35:785.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.